Literature DB >> 17884183

CCL5 and CCR5 genotypes modify clinical, radiological and pathological features of multiple sclerosis.

Tineke van Veen1, Jessica Nielsen, Johannes Berkhof, Frederik Barkhof, Wouter Kamphorst, Lars Bö, Rivka Ravid, Cor L Verweij, Inge Huitinga, Chris H Polman, Bernard M J Uitdehaag.   

Abstract

Chemokines mediate selective recruitment of leukocyte subsets into the CNS during inflammatory episodes. We hypothesised that functional polymorphisms in CCR5 and CCL5 influence perivascular leukocyte infiltration, inflammation, axonal loss, and remyelination, and disease course. Therefore, we determined genotypes at four possibly functional polymorphisms in CCR5 and CCL5 for 637 patients and 92 brain donors with multiple sclerosis (MS). For a subset of 192 patients, MRI data were available. We found that low-producer allele CCL5-403*G was associated with reduced risk of severe axonal loss, whereas high-producer allele CCL5-403*A was associated with a worse clinical disease course measured by the MS Functional Composite Score and MS Severity Score. Low-producer allele CCR5+303*G was associated with reduced T2 hyperintense and T1 hypointense lesion volumes on MRI, and high-producer allele CCR5+303*A with early age at onset. Furthermore, low-producer allele CCR5Delta32 was associated with reduced T2 lesion volume, lower black hole ratio on MRI, and with a higher percentage of lesions with signs of remyelination, histopathologically. In summary, our multifaceted study supports the notion that polymorphisms in CCL5 and CCR5 modify the course of MS.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17884183     DOI: 10.1016/j.jneuroim.2007.08.005

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  17 in total

Review 1.  CCR5 blockade for neuroinflammatory diseases--beyond control of HIV.

Authors:  Guillaume Martin-Blondel; David Brassat; Jan Bauer; Hans Lassmann; Roland S Liblau
Journal:  Nat Rev Neurol       Date:  2016-01-18       Impact factor: 42.937

2.  Genetic correlations of brain lesion distribution in multiple sclerosis: an exploratory study.

Authors:  M H Sombekke; M M Vellinga; B M J Uitdehaag; F Barkhof; C H Polman; D Arteta; D Tejedor; A Martinez; J B A Crusius; A S Peña; J J G Geurts; H Vrenken
Journal:  AJNR Am J Neuroradiol       Date:  2011-03-24       Impact factor: 3.825

Review 3.  Role of platelets in neuroinflammation: a wide-angle perspective.

Authors:  Lawrence L Horstman; Wenche Jy; Yeon S Ahn; Robert Zivadinov; Amir H Maghzi; Masoud Etemadifar; J Steven Alexander; Alireza Minagar
Journal:  J Neuroinflammation       Date:  2010-02-03       Impact factor: 8.322

4.  Transcriptomics of cortical gray matter thickness decline during normal aging.

Authors:  P Kochunov; J Charlesworth; A Winkler; L E Hong; T E Nichols; J E Curran; E Sprooten; N Jahanshad; P M Thompson; M P Johnson; J W Kent; B A Landman; B Mitchell; S A Cole; T D Dyer; E K Moses; H H H Goring; L Almasy; R Duggirala; R L Olvera; D C Glahn; J Blangero
Journal:  Neuroimage       Date:  2013-05-24       Impact factor: 6.556

5.  Decreased spinal cord opioid receptor mRNA expression and antinociception in a Theiler's murine encephalomyelitis virus model of multiple sclerosis.

Authors:  Jessica L Lynch; Jeremy F Alley; Lori Wellman; Alvin J Beitz
Journal:  Brain Res       Date:  2007-11-28       Impact factor: 3.252

Review 6.  Pediatric multiple sclerosis.

Authors:  Dorothee Chabas; Jonathan Strober; Emmanuelle Waubant
Journal:  Curr Neurol Neurosci Rep       Date:  2008-09       Impact factor: 5.081

7.  An MRI-defined measure of cerebral lesion severity to assess therapeutic effects in multiple sclerosis.

Authors:  Gloria Kim; Shahamat Tauhid; Sheena L Dupuy; Subhash Tummala; Fariha Khalid; Brian C Healy; Rohit Bakshi
Journal:  J Neurol       Date:  2016-01-11       Impact factor: 4.849

Review 8.  CCL5-Glutamate Cross-Talk in Astrocyte-Neuron Communication in Multiple Sclerosis.

Authors:  Anna Pittaluga
Journal:  Front Immunol       Date:  2017-09-04       Impact factor: 7.561

Review 9.  The Expanding Therapeutic Perspective of CCR5 Blockade.

Authors:  Luca Vangelista; Sandro Vento
Journal:  Front Immunol       Date:  2018-01-12       Impact factor: 7.561

10.  RANTES/CCL5 Signaling from Jawbone Cavitations to Epistemology of Multiple Sclerosis - Research and Case Studies.

Authors:  Johann Lechner; Volker von Baehr; Fabian Schick
Journal:  Degener Neurol Neuromuscul Dis       Date:  2021-07-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.